GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wockhardt Ltd (NSE:WOCKPHARMA) » Definitions » Cyclically Adjusted Revenue per Share

Wockhardt (NSE:WOCKPHARMA) Cyclically Adjusted Revenue per Share : ₹341.76 (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is Wockhardt Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Wockhardt's adjusted revenue per share for the three months ended in Mar. 2025 was ₹48.112. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹341.76 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Wockhardt's average Cyclically Adjusted Revenue Growth Rate was -8.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -8.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Wockhardt was -3.70% per year. The lowest was -8.10% per year. And the median was -6.20% per year.

As of today (2025-06-26), Wockhardt's current stock price is ₹1655.70. Wockhardt's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹341.76. Wockhardt's Cyclically Adjusted PS Ratio of today is 4.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Wockhardt was 5.20. The lowest was 0.38. And the median was 0.86.


Wockhardt Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Wockhardt's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wockhardt Cyclically Adjusted Revenue per Share Chart

Wockhardt Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 449.54 440.49 402.40 372.99 341.76

Wockhardt Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 372.99 369.79 365.77 353.45 341.76

Competitive Comparison of Wockhardt's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wockhardt's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wockhardt's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Wockhardt's Cyclically Adjusted PS Ratio falls into.


;
;

Wockhardt Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Wockhardt's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=48.112/157.5517*157.5517
=48.112

Current CPI (Mar. 2025) = 157.5517.

Wockhardt Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 94.084 99.841 148.468
201509 101.850 101.753 157.701
201512 88.930 102.901 136.161
201603 84.791 102.518 130.308
201606 90.464 105.961 134.509
201609 88.198 105.961 131.140
201612 83.047 105.196 124.379
201703 72.006 105.196 107.843
201706 74.283 107.109 109.267
201709 84.870 109.021 122.649
201712 83.867 109.404 120.776
201803 84.819 109.786 121.722
201806 83.940 111.317 118.804
201809 93.848 115.142 128.415
201812 87.013 115.142 119.062
201903 30.037 118.202 40.036
201906 60.353 120.880 78.663
201909 56.826 123.175 72.685
201912 62.323 126.235 77.784
202003 55.347 124.705 69.925
202006 49.593 127.000 61.523
202009 59.314 130.118 71.820
202012 63.292 130.889 76.185
202103 51.704 131.771 61.820
202106 69.461 134.084 81.618
202109 70.735 135.847 82.037
202112 71.017 138.161 80.984
202203 44.079 138.822 50.026
202206 41.206 142.347 45.607
202209 47.243 144.661 51.453
202212 48.202 145.763 52.100
202303 46.793 146.865 50.198
202306 44.599 150.280 46.757
202309 52.514 151.492 54.615
202312 48.563 152.924 50.032
202403 48.112 153.035 49.532
202406 50.147 155.789 50.714
202409 54.056 157.882 53.943
202412 46.865 158.323 46.637
202503 48.112 157.552 48.112

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Wockhardt  (NSE:WOCKPHARMA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Wockhardt's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1655.70/341.76
=4.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Wockhardt was 5.20. The lowest was 0.38. And the median was 0.86.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Wockhardt Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Wockhardt's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Wockhardt Business Description

Industry
Traded in Other Exchanges
Address
Wockhardt Towers, Bandra-Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The company conducts research in the fields of pharmaceuticals and biotechnology while also operating its chain of Super Specialty Hospitals. The vast majority of the company's revenue is generated in Europe. The company also operates in the USA, Japan, Russia, and Rest of the world.

Wockhardt Headlines

No Headlines